In the Margins

Sequoia Fund's Valeant bet highlights concentration risks

November 2, 2015

By The Wall Street Journal

Concentrated bets on individual stocks raise issues for mutual funds and their investors—a matter highlighted last week at Sequoia Fund, one of the biggest investors in controversial drug maker Valeant Pharmaceuticals International Inc. Placing outsize bets on well-chosen stocks can lead to strong performance, but concentration increases the riskiness of a fund and raises questions about how much is too much. Read the original story from The Wall Street Journal.

 

 

Most Read

Top of the Agenda - Governance
ASA board enlarged, timeline to AGM unclear

ASA Gold and Precious Metals Ltd. shareholders voted at a special meeting last week to enlarge the closed-end fund's board and elected a fifth independent director, one ...